Janssen has already produced a number of patient guides in close cooperation with the organizations that are active in the field of a particular disease, such as depression, IBD and lymphoma. These guides are characterized by testimonials and accessible language, with much attention paid to the emotional aspects of the disease and to the impact on the patient's daily life and environment. The testimonials and feedback from patients are first and foremost valuable to fellow sufferers. But these insights are also incredibly useful for shaping our future choices and vision as a healthcare company. In addition to the final result, the intensive process that we have completed together with these associations is also invaluable.

Janssen firmly believes that the voice of the patient is an indispensable link in our way of working. This is why we place a great deal of focus on information sharing and co-creation with patient associations in our processes and projects. Complementarity and equality are the code words here.

Unfortunately, many people have to deal with the consequences of cancer in their lives - either themselves or when someone close to them is confronted by it. In addition to our mission to develop treatments that can reduce and ultimately cure this terrible disease, we are also committed to making the daily lives of patients and their families more bearable. For example, cancer often has a major impact on work. Work is an important part of the quality of life. For many people, a job is not only having an income, but also a source of meaning. As people live longer and longer due to improving treatments, (the return to) work becomes even more important. This is why we work closely together with people and organizations that are close to patients. For example, Janssen works together with Travail & Cancer, an organization that specializes in coaching aimed at returning to work.¹² Thanks to this partnership, the "Empowerme" app was realized, which focuses on regaining one's independence.¹³  Also with the Foundation against Cancer, we intensified our collaboration on 'reintegration and work' during and after the illness.¹⁴ 

At Janssen, we are always looking for ways to improve the transfer of our knowledge. We are also looking at new multimedia techniques, such as the podcast. For example, Janssen launched its Spotify channel in 2020 with a brand new series of podcasts on inflammatory bowel disease (IBD) and fatigue. In this way, patients and their loved ones can listen to conversations between experts and experts by experience, whenever and wherever they want. And it doesn't stop there. The knowledge we gain about the virtual organization of events is also shared with different patient associations through various webinars.

At Janssen, we are working on a future in which disease is a thing of the past. This ambition can only be achieved if everyone - everywhere in the world - has access to the right medication and treatments. Although global health care has improved significantly in recent decades, there are still major health challenges in many places that require our urgent attention.

Global Public Health is an end-to-end organization within Johnson & Johnson that works every day to address the greatest health challenges in the world's most vulnerable places, such as developing countries. Its activities range widely, from R&D to the healthcare teams with both feet in the field. Global Public Health focuses on five challenges: eliminating HIV and tuberculosis, preventing, and responding appropriately to future pandemics, combating neglected tropical diseases, combating antibiotic resistance, and addressing mental illness in resource-poor areas.

For example, a safe and effective vaccine is still not available for many infectious diseases. But the impact of these diseases remains significant. Tuberculosis is unfortunately a telling example: it claims the most victims among infectious diseases⁵, including in China and India. GPH therefore continues to invest in drugs and vaccines against common infectious diseases. In 2014, a new Janssen drug for multidrug-resistant tuberculosis was approved by the competent authorities. Janssen donated 30,000 doses of this drug, worth 25 million euros, shortly after its development to the U.S. Agency for International Development, which made it available as a global TB treatment. 

And we also want to consign HIV to the history books. Janssen has already developed nine transformational treatments. Pediatric HIV care, both in children and adolescents, receives our unwavering support. Since 2014, we have been realizing access to our second- and third-line HIV medicines in the eleven participating countries in sub-Saharan Africa within the New Horizons Collaborative. In Uganda, we are even deploying drones to still get our antiretroviral treatments to the most challenging locations, such as remote islands. We will only be able to truly halt the HIV pandemic thanks to an effective and safe vaccine, as we already developed for Ebola and COVID-19. With two large-scale efficacy studies on four continents for our candidate HIV vaccine, we hope to be able to realize this ambition in the future.